News | October 28, 2013

Valve-In-Valve Implants Provide Option for People With Adult Congenital Heart Disease Without Open Heart Surgery

heart valve repair valve-in-valve melody transcatheter pulmonary houston
October 28, 2013 — A new valve recently approved by the U.S. Food and Drug Administration (FDA) now gives heart patients a new way to manage their disease without having to undergo open heart surgery.?
 
The Melody Transcatheter Pulmonary Valve, which is delivered through a catheter and requires only a small incision, is a new technique that is bringing new hope to these patients with congenital heart disease.
 
C. Huie Lin, M.D., Ph.D., adult congenital heart disease specialist, recently implanted the first Melody Valve at Methodist DeBakey Heart and Vascular Center, Houston, in a young man who had already had three open heart surgeries for congenital heart disease. ??“More than a million people live with adult congenital heart disease in the U.S., and we expect that number to grow by 5 percent each year,” Lin said. “I believe this new Melody Valve is a great new option for people who were no longer candidates for surgery.”
 
Lin said the Melody Valve helps patients who have already had an open heart surgery for congenital heart disease and have developed problems with the valve leaking or becoming blocked.??The valve, made for the right side of the heart, is designed to be implanted inside of the existing valve. Made from the internal jugular vein of a cow, the valve is sewn onto a stent and the stent is then put onto a balloon catheter. The catheter is then placed through the femoral vein and advanced to the pulmonary valve position. The balloon then expands and deploys the valve.??“Because it’s implanted inside of an existing valve, a new Melody valve can also be implanted in an existing Melody valve if it’s not working properly,” Lin said. “It’s a revolutionary technique.”
 
For more information: www.medtronic.com, www.houstonmethodist.org

Related Content

Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology | December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology | November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology | November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology | November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Videos | Heart Valve Technology | November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Overlay Init